Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Lumateperone - Intra-Cellular Therapies

X
Search
Drug Profile

Lumateperone - Intra-Cellular Therapies

Alternative Names: CAPLYTA; ITI-007; ITI-722; Lumateperone tosylate

Latest Information Update: 18 Oct 2024

Price : ¥7190 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Intra-Cellular Therapies
  • Class Antidementias; Antidepressants; Antipsychotics; Behavioural disorder therapies; Fluorobenzenes; Piperidines; Pyrroles; Quinoxalines; Sleep disorder therapies; Small molecules; Tosyl compounds
  • Mechanism of Action Dopamine D2 receptor modulators; Glutamate modulators; Serotonin 2A receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar depression; Schizophrenia
  • Phase III Behavioural disorders; Bipolar disorders; Major depressive disorder
  • Phase II Sleep maintenance insomnia

Most Recent Events

  • 23 Aug 2024 Phase-I clinical trials in Schizophrenia in USA (IM) (NCT06627413)
  • 23 Aug 2024 Intra-Cellular Therapies initiated a Phase-I clinical trials in Schizophrenia in USA (PO) (NCT06627413)
  • 07 Aug 2024 Intra-Cellular Therapies plans two clinical trials for Autism spectrum disorder (In children) in the second half of 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days